Review
Oncology
Serenella M. Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri, Lorenzo Castagnoli
Summary: Breast cancer is a group of different tumors, with altered HER2 expression defining a particularly aggressive subtype. Understanding HER2 biology and the mechanisms underlying aggressiveness and drug susceptibility is crucial. Breast cancer stem cells play a significant role in tumor growth, aggressiveness, metastasis, and treatment resistance.
Article
Pharmacology & Pharmacy
Bo-Wei Wang, Chih-Hao Huang, Liang-Chih Liu, Fang-Ju Cheng, Ya-Ling Wei, Yueh-Ming Lin, Yu-Fei Wang, Ching-Ting Wei, Yeh Chen, Yun-Ju Chen, Wei-Chien Huang
Summary: Pim1 kinase is closely associated with HER2 expression and its inhibitor can effectively downregulate HER2 expression and overcome resistance to HER2 tyrosine kinase inhibitor in breast cancer cells.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Christopher E. Eyermann, Jinyu Li, Evguenia M. Alexandrova
Summary: Pregnancy is known to reduce the risk of breast cancer, but it may promote HER2+ BC. Studies have shown that pregnancy can increase the incidence of HER2+ BC in mice models, possibly linked to the tumor-initiating properties of PIMECs. The gene p63 plays a complex role in maintaining PIMEC quantity while suppressing their tumorigenic capacity.
CELL DEATH & DISEASE
(2021)
Review
Oncology
Santiago Duro-Sanchez, Macarena Roman Alonso, Joaquin Arribas
Summary: A variety of treatments are available for HER2-positive breast cancer, but resistance to these therapies is common and associated with poor prognosis. Immunotherapeutic approaches are being explored to eradicate tumor cells and prevent relapse and progression. This review discusses the different immunotherapeutic strategies being tested and their potential benefits for HER2-positive breast cancer.
Article
Cell & Tissue Engineering
Yan Qiu, Libo Yang, Honghong Liu, Xiaobo Luo
Summary: The use of the anti-HER2 drug trastuzumab has significantly improved the prognosis of HER2-positive breast cancer patients, but 50% of patients relapse due to trastuzumab resistance, which is closely related to the presence of breast cancer stem cells (BCSCs). BCSCs are resistant to conventional therapy and may drive distant metastasis and cancer relapse.
Article
Cell Biology
Yongguang Yang, Marissa Leonard, Zhenhua Luo, Syn Yeo, Gregory Bick, Mingang Hao, Chunmiao Cai, Mahmoud Charif, Jiang Wang, Jun-Lin Guan, Elyse E. Lower, Xiaoting Zhang
Summary: The study reveals the crucial role of MED1 in HER2-driven mammary tumorigenesis, showing that its overexpression can significantly promote the onset, growth, metastasis, and multiplicity of HER2 tumors. Further investigations demonstrate that MED1 is involved in epithelial-mesenchymal transition, cancer stem cell formation, and response to anti-HER2 therapy. Additionally, the research identifies Jab1 as the key target gene of MED1 contributing to these processes and shows a reciprocal regulation between Jab1 and MED1.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Review
Oncology
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Summary: Triple-positive breast tumors overexpress HER2 and are positive for HR expression. ER expression affects the response to anti-HER2 and associated systemic therapies. Optimizing dual anti-HER2 blockade is important for disease control in triple-positive tumors.
CANCER TREATMENT REVIEWS
(2023)
Review
Biotechnology & Applied Microbiology
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Summary: The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2(+) breast cancer. Here, Swain et al. review the current standard of care for HER2(+) breast cancer, describe mechanisms of drug resistance, and focus on next-generation platforms and therapies for the treatment of this disease.
NATURE REVIEWS DRUG DISCOVERY
(2023)
Article
Chemistry, Multidisciplinary
Delaram Parvin, Zahra Sadat Hashemi, Farhad Shokati, Zahra Mohammadpour, Vahid Bazargan
Summary: By integrating magnetic nanoparticles with microfluidics, an effective and low-cost method for isolating HER2-positive breast cancer cells was developed, which improved the efficiency of cell isolation and reduced the analysis time. This microfluidic system offers a competitive solution for clinical applications.
Article
Multidisciplinary Sciences
Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Kelly McKenna, Stephen Willingham, Po Yi Ho, Benyamin Rosental, Michal Caspi Tal, Tal Raveh, Jens-Peter Volkmer, Mark D. Pegram, Irving L. Weissman
Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Muhammad Raisul Abedin, Kaitlyne Powers, Rachel Aiardo, Dibbya Barua, Sutapa Barua
Summary: Novel antibody-drug nanoparticles were designed for targeted and efficient anti-cancer therapy through selective targeting and cancer cell death via apoptosis and mitotic cell cycle arrest, showing higher therapeutic efficiency compared to individual drug treatments.
SCIENTIFIC REPORTS
(2021)
Article
Genetics & Heredity
Xi Jin, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai-Jin Lin, Yi Xiao, Tong Fu, Cheng-Lin Liu, Yi-Yu Chen, Wen-Xuan Xiao, Ya-Qing Liu, Qing-Wang Chen, Ying Yu, Le-Ming Shi, Jin-Xiu Shi, Wei Huang, John F. R. Robertson, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: This study establishes a large-scale multi-omics cohort of HR+/HER2- breast cancer patients and identifies four molecular subtypes. These subtypes have distinct biological and clinical features, providing insights for precision treatment.
Article
Oncology
Soeun Park, Jung Min Park, Minsu Park, Dongmi Ko, Seongjae Kim, Juyeon Seo, Kee Dal Nam, Eunsun Jung, Lee Farrand, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Summary: This study found that beta-escin could enhance the inhibitory effect on trastuzumab resistance by inducing mitochondrial-mediated apoptosis, reducing CSC-like properties, and hindering mammosphere formation. Additionally, beta-escin showed lower toxicity to normal cells.
CANCER CELL INTERNATIONAL
(2022)
Review
Medicine, General & Internal
Lixi Li, Di Zhang, Binliang Liu, Dan Lv, Jingtong Zhai, Xiuwen Guan, Zongbi Yi, Fei Ma
Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs, and have shown potential as a promising treatment option for breast cancer and other tumors.
CHINESE MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Mostafa Keshavarz, Malek Hossein Asadi
Article
Biochemistry & Molecular Biology
Forough Hakiminia, Firooz Jannat Alipoor, Mostafa Keshavarz, Malek Hossein Asadi
Summary: Long non-coding RNA PNKY is significantly upregulated in breast tumors and plays a crucial role in the proliferation, migration, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Knock down of PNKY restricts cell proliferation by promoting apoptosis, senescence, and cell cycle disruption, and PNKY may trigger EMT by upregulating miR-150 and restricting the expression of Zeb1 and Snail. This study provides new evidence on the expression and biological function of PNKY in cancer cells, highlighting its potential contribution to tumor growth and metastasis.